AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.
With US government supplies of Covid vaccines predicted to run out in the first quarter of 2023, it has been revealed that Pfizer/BioNTech plans to charge as much as $130 for its Covid vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback